| Dr Philip Arthur Flexo, PHD | |
|
337 S Beverly Dr, Suite 209, Beverly Hills, CA 90212 | |
| (310) 553-0066 | |
| Not Available |
| Full Name | Dr Philip Arthur Flexo |
|---|---|
| Gender | Male |
| Speciality | Psychologist - Clinical |
| Location | 337 S Beverly Dr, Beverly Hills, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033321104 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PSY 5320 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Philip Arthur Flexo, PHD 337 S Beverly Dr, Suite 209, Beverly Hills, CA 90212 Ph: (310) 553-0066 | Dr Philip Arthur Flexo, PHD 337 S Beverly Dr, Suite 209, Beverly Hills, CA 90212 Ph: (310) 553-0066 |
News Archive
GE Healthcare today announced that it has submitted an application to amend its European Marketing Authorisation that will allow the company to manufacture Optison 0.19 mg/ml dispersion for injection within its own facility.
Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma.
Medifast, Inc., a leading provider of clinically proven portion-controlled weight-loss programs, today reported financial results for the second quarter ended June 30, 2010.
"Calculating the number of hungry people around the world at any given moment, let alone predicting how that number is likely to change in the future, is no easy task," Reuters reports in an article examining the numerous challenges of estimating the number of undernourished people worldwide and noting the U.N. Food and Agriculture Organization (FAO) is expected to release new data and methodology in October "as part of its annual report on food insecurity."
Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.
› Verified 5 days ago
Dr. Lindsay Heller, PSY.D. Psychologist Medicare: Medicare Enrolled Practice Location: 9171 Wilshire Blvd Ste 600, Beverly Hills, CA 90210 Phone: 310-384-9300 Fax: 310-283-1010 | |
Dr. Susan Himelstein, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 9107 Wilshire Blvd, Suite 215, Beverly Hills, CA 90210 Phone: 310-247-9447 Fax: 323-299-2988 | |
Dr. Lucia M Melito, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 337 S Beverly Dr, 212, Beverly Hills, CA 90212 Phone: 310-858-8117 | |
Vivien Armalie Zighelboim, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 9730 Wilshire Blvd, Suite 214, Beverly Hills, CA 90212 Phone: 310-277-4389 | |
Dr. Terry Simpson, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 9454 Wilshire Blvd, Penthouse 1026-a, Beverly Hills, CA 90212 Phone: 424-253-8788 | |
Daryn Plancher, PH.D., Psychologist Medicare: Not Enrolled in Medicare Practice Location: 9171 Wilshire Blvd, Penthouse, Beverly Hills, CA 90210 Phone: 310-709-3088 |